Three insights:
1. IDCT’s safety and efficacy will be evaluated in 60 participants with single-level, mild to moderate lumbar degenerative disc disease.
2. The Phase 1/2 clinical trial aims to show IDCT’s ability to reduce inflammation and restore disc height.
3. The prospective, randomized trial will take place at 14 centers in 12 states.
More articles on devices:
Rothman Orthopaedics surgeon to lead orthopedic oncology program
New Southeastern Spine Institute moves closer to completion
Kevin Lobo’s 8+ years as Stryker CEO: Leading 20+ acquisitions, boosting robotics & more
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
